Mast cell activation syndrome

Overview

Mast Cell Activation Syndrome (MCAS) is a condition where mast cells, a type of immune cell, release too many inflammatory chemicals at inappropriate times. These chemicals, known as mediators, can affect many different parts of the body, leading to a broad spectrum of symptoms. Unlike mastocytosis, where there is an abnormal increase in the number of mast cells, MCAS primarily involves dysfunctional mast cell behaviour, although some individuals may have both conditions [PMID:33675005].

Mast cells play a crucial role in the immune system, protecting the body from pathogens and toxins, and are involved in allergic reactions. They are found in almost all tissues, particularly in areas that interact with the external environment, such as the skin, lungs, and gut. In MCAS, these cells become overactive, leading to chronic or recurrent symptoms that can be mild or severe.

Symptoms & clinical features

The symptoms of MCAS are highly varied and can affect almost any organ system due to the widespread presence of mast cells. Common symptoms often include skin issues like flushing, itching, hives (urticaria), and swelling (angioedema). Gastrointestinal problems are also frequently reported, such as abdominal pain, diarrhoea, nausea, and vomiting [PMID:33675005].

Respiratory symptoms might involve wheezing, shortness of breath, and nasal congestion. Cardiovascular effects can include dizziness, lightheadedness, and rapid heart rate (tachycardia). Neurological symptoms like headaches, brain fog, and fatigue are also common. Allergic-like reactions, including anaphylaxis, can occur in severe cases, even without a clear allergen trigger [PMID:32766829]. The unpredictable nature and variability of symptoms can make MCAS challenging to diagnose.

Video: Genetics 101

Affected organs

Because mast cells are present in almost all tissues, MCAS can affect a wide range of organs and body systems. The most commonly impacted systems include the skin (causing rashes, flushing, itching), the gastrointestinal tract (leading to abdominal discomfort, diarrhoea), and the cardiovascular system (resulting in rapid heart rate, low blood pressure, fainting). Respiratory symptoms often involve the lungs and nasal passages.

The nervous system can also be affected, contributing to symptoms such as headaches, cognitive difficulties, and fatigue. In some cases, the skeletal system may show signs of osteopenia or osteoporosis. The systemic release of mast cell mediators can also cause general symptoms like profound fatigue, malaise, and allergic-like reactions.

Immune cells

Immune system dysfunction

Cellular impact

Mechanism at cellular level

Risks & severity

The severity of MCAS can vary significantly among individuals, ranging from mild, intermittent symptoms to severe, life-threatening episodes resembling anaphylaxis. The exact prevalence of MCAS is not well established, but it is thought to be more common than previously recognised, though often underdiagnosed due to its broad and non-specific symptoms. Some individuals may experience chronic symptoms that significantly impact their quality of life, while others might have acute flares triggered by various factors.

Triggers can include certain foods, medications, stress, temperature changes, infections, and even exercise. While MCAS is not typically considered life-limiting, severe reactions, such as anaphylaxis, can be dangerous if not promptly treated. Long-term implications may involve chronic pain, persistent fatigue, and reduced quality of life if the condition is not managed effectively.

Genetic causes

MCAS is considered a complex or polygenic condition, meaning that it is likely influenced by a combination of genetic factors and environmental triggers. While a specific inheritance pattern like autosomal dominant or recessive is not typically observed, research suggests that certain genetic variations may predispose individuals to developing MCAS.

One gene that has been studied in the context of mast cell disorders is *KIT*. *KIT* provides instructions for making a protein called KIT receptor tyrosine kinase, which is crucial for the development, survival, and function of mast cells. Variations in *KIT* have been associated with altered mast cell behaviour and, in some cases, with conditions like mastocytosis, which shares some features with MCAS [PMID:32766829]. While a direct causative link between *KIT* variants and MCAS is still an area of active research, alterations in genes influencing mast cell development and activation are thought to play a role in the underlying susceptibility.

Inheritance pattern

Mast Cell Activation Syndrome (MCAS) is generally considered to have a complex or polygenic inheritance pattern. This means that its development is not usually due to a single gene mutation passed down in a straightforward manner. Instead, multiple genetic factors, each contributing a small effect, combine with environmental influences to increase an individual's susceptibility to the condition.

Therefore, while there may be a tendency for MCAS to run in families, it does not follow the clear patterns seen in single-gene disorders. Predicting the likelihood of relatives developing MCAS can be challenging, as it depends on the specific combination of genetic predispositions and exposure to various environmental triggers. Genetic counselling may be helpful for families with multiple affected members to understand these complex inheritance patterns.

Diagnosis & testing

Diagnosing MCAS can be challenging due to its diverse and non-specific symptoms, which often mimic other conditions. The diagnosis typically involves a combination of clinical criteria, such as experiencing recurrent episodes of symptoms affecting multiple organ systems, and evidence of mast cell mediator release. Blood or urine tests may be performed during symptomatic episodes to measure levels of mast cell mediators, such as tryptase, histamine, and prostaglandin D2 metabolites [PMID:33675005].

Genetic testing for specific gene variants, such as those in *KIT*, may be considered in some contexts, particularly to differentiate MCAS from mastocytosis or to investigate potential genetic predispositions. In the UK, if MCAS is suspected, a referral to an immunology or allergy specialist, or a clinical geneticist in complex cases, would be part of the NHS care pathway. There isn't a specific R-code for MCAS genetic testing at present, as diagnosis relies primarily on clinical and biochemical findings.

Management & lifestyle

Managing MCAS focuses on controlling symptoms and preventing acute episodes, as there is currently no cure for the underlying condition. Treatment strategies are highly individualised and often involve identifying and avoiding known triggers. Medications commonly used include H1 and H2 antihistamines to block the effects of histamine, mast cell stabilisers (such as cromoglicate) to reduce mediator release, and in some cases, leukotriene inhibitors [PMID:32766829].

For severe reactions, adrenaline auto-injectors may be prescribed. Lifestyle modifications, including dietary changes and stress management techniques, can also play a role. Management typically falls under the care of an immunologist or allergist within the NHS. Individuals are often encouraged to work closely with their healthcare team to develop a comprehensive management plan that addresses their specific symptoms and improves their quality of life.

UK care pathway

For individuals in the UK suspected of having Mast Cell Activation Syndrome, the care pathway typically begins with a referral from a GP to a specialist, often an immunologist or allergist, within the NHS. These specialists are experienced in diagnosing and managing complex conditions affecting the immune system. If genetic factors are considered relevant, perhaps in cases with a family history or atypical presentation, a referral to Clinical Genetics services might be made.

Genetic counsellors within these services provide information and support to individuals and families regarding genetic conditions, inheritance patterns, and the implications of genetic testing. While specific NHS R-codes for MCAS genetic testing are not currently routine, the NHS Genomic Medicine Service is evolving, and relevant investigations would be coordinated through specialist teams.

Related conditions

MCAS shares some clinical features with other conditions, making differentiation important for accurate diagnosis. Systemic mastocytosis, for example, is a condition characterised by an abnormal accumulation of mast cells in various tissues, and while it involves mast cell activation, it is distinct from MCAS. Allergic reactions and anaphylaxis can present similarly to MCAS flares, but typically have clear allergen triggers.

Other conditions that might present with overlapping symptoms include irritable bowel syndrome (IBS) for gastrointestinal issues, chronic urticaria for skin manifestations, and dysautonomia for autonomic symptoms. Ehlers-Danlos syndrome, a connective tissue disorder, is also sometimes found in individuals with MCAS, suggesting a potential co-occurrence, although the precise relationship is still being researched.

Frequently asked questions

References

1. Castells M, Giannetti MP, Hamilton MJ. Mast cell activation syndrome: Current understanding and research needs. The Journal of allergy and clinical immunology. 2024. PMID: 38851398
2. Afrin LB, Weinstock LB, Dempsey TT. Utility of glucagon-like-peptide-1-receptor agonists in mast cell activation syndrome. The American journal of the medical sciences. 2025. PMID: 40675372
3. Afrin LB, Ackerley MB, Bluestein LS. Diagnosis of mast cell activation syndrome: a global "consensus-2". Diagnosis (Berlin, Germany). 2021. PMID: 32324159
4. Hamilton MJ. Mast Cell Activation Syndrome and Gut Dysfunction: Diagnosis and Management. Current gastroenterology reports. 2024. PMID: 38353900
5. Weiler CR. Mast Cell Activation Syndrome: Tools for Diagnosis and Differential Diagnosis. The journal of allergy and clinical immunology. In practice. 2020. PMID: 31470118
6. Gulen T. Using the Right Criteria for MCAS. Current allergy and asthma reports. 2024. PMID: 38243020
7. Weinstock LB, Pace LA, Rezaie A. Mast Cell Activation Syndrome: A Primer for the Gastroenterologist. Digestive diseases and sciences. 2021. PMID: 32328892
8. Castells M, Butterfield J. Mast Cell Activation Syndrome and Mastocytosis: Initial Treatment Options and Long-Term Management. The journal of allergy and clinical immunology. In practice. 2019. PMID: 30961835